Check for updates

OPEN ACCESS

EDITED BY Hongfu Sun, The University of Queensland, Australia

REVIEWED BY

Thomas Samuel Ram, Christian Medical College and Hospital, India Raghunadharao Digumarti, MNJ Institute of Oncology & Regional Cancer Centre, India

*CORRESPONDENCE Tianliang Shi Xycshuang68@163.com

RECEIVED 29 April 2024 ACCEPTED 26 September 2024 PUBLISHED 17 October 2024

CITATION

Yang C, Wu M, Zhang J, Qian H, Fu X, Yang J, Luo Y, Qin Z and Shi T (2024) Radiomics based on MRI in predicting lymphovascular space invasion of cervical cancer: a meta-analysis. *Front. Oncol.* 14:1425078. doi: 10.3389/fonc.2024.1425078

COPYRIGHT

© 2024 Yang, Wu, Zhang, Qian, Fu, Yang, Luo, Qin and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Radiomics based on MRI in predicting lymphovascular space invasion of cervical cancer: a meta-analysis

Chongshuang Yang¹, Min Wu¹, Jiancheng Zhang¹, Hongwei Qian¹, Xiangyang Fu^{1,2}, Jing Yang¹, Yingbin Luo¹, Zhihong Qin¹ and Tianliang Shi^{1*}

¹Department of Radiology, Tongren People's Hospital, Tongren, China, ²Department of Radiology, Wanshan District People's Hospital, Tongren, China

Objective: The objective of this meta-analysis is to assess the efficacy of radiomics techniques utilizing magnetic resonance imaging (MRI) for predicting lymphovascular space invasion (LVSI) in patients with cervical cancer (CC).

Methods: A comprehensive literature search was conducted in databases including PubMed, Embase, Cochrane Library, Medline, Scopus, CNKI, and Wanfang, with studies published up to 08/04/2024, being considered for inclusion. The meta-analysis was performed using Stata 15 and Review Manager 5.4. The quality of the included studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2 and Radiomics Quality Score tools. The analysis encompassed the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Summary ROC curves were constructed, and the AUC was calculated. Heterogeneity was investigated using meta-regression. Statistical significance was set at $p \le 0.05$.

Results: There were 13 studies involving a total of 2,245 patients that were included in the meta-analysis. The overall sensitivity and specificity of the MRIbased model in the Training set were 83% (95% CI: 77%-87%) and 72% (95% CI: 74%-88%), respectively. The AUC, DOR, PLR, and NLR of the MRI-based model in the Training set were 0.89 (95% CI: 0.86-0.91), 22 (95% CI: 12-40), 4.6 (95% CI: 3.1–7.0), and 0.21 (95% CI: 0.16–0.29), respectively. Subgroup analysis revealed that the AUC of the model combining radiomics with clinical factors [0.90 (95% CI: 0.87-0.93)] was superior to models based on T2-weighted imaging (T2WI) sequence [0.78 (95% CI: 0.74-0.81)], contrast-enhanced T1-weighted imaging (T1WI-CE) sequence [0.85 (95% CI: 0.82-0.88)], and multiple sequences [0.86 (95% CI: 0.82–0.89)] in the Training set. The pooled sensitivity and specificity of the model integrating radiomics with clinical factors [83% (95% CI: 73%-89%) and 86% (95% CI: 73%-93%)] surpassed those of models based on the T2WI sequence [79% (95% CI: 71%-85%) and 72% (95% CI: 67%-76%)], T1WI-CE sequence [78% (95% CI: 67%-86%) and 78% (95% CI: 68%-86%)], and multiple sequences [78% (95% CI: 67%-87%) and 79% (95% CI: 70%-87%)], respectively. Funnel plot analysis indicated an absence of publication bias (p > 0.05).

Conclusion: MRI-based radiomics demonstrates excellent diagnostic performance in predicting LVSI in CC patients. The diagnostic performance of models combing radiomics and clinical factors is superior to that of models utilizing radiomics alone.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ #myprospero, identifier CRD42024538007.

KEYWORDS

cervical cancer, radiomics, magnetic resonance imaging, systematic review, lymphovascular space invasion

1 Introduction

Cervical cancer (CC) ranks as the fourth most prevalent cancer among women globally. In 2020, statistics reported approximately 604,000 new cases and 342,000 deaths worldwide (1, 2). Lymphovascular space invasion (LVSI), as the name indicates, occurs when cancer cells invade the blood vessels or lymphatics. This process is a critical step in the metastasis of cancer cells to other locations or organs (3). The National Comprehensive Cancer Network (NCCN) guidelines for CC consider LVSI a critical determinant in selecting appropriate treatment plans. Early-stage CC with or without LVSI requires markedly different therapeutic approaches. For CC patients with International Federation of Gynecology and Obstetrics (FIGO) IA1 stage, conization is recommended for tumors without LVSI. However, patients with LVSI, even at the IA1 stage, require radical hysterectomy and pelvic lymph node dissection. Therefore, preoperative determination of LVSI plays a pivotal role in patient surgical planning and systemic treatment (4).

Magnetic resonance imaging (MRI) is the most commonly used imaging methods for CC evaluation, and MRI-based assessment has significantly improved the accuracy of CC diagnosis in recent decades (5). Although functional MRI techniques, including dynamic contrastenhanced MRI (DCE-MRI), amide proton transfer imaging, and diffusion-weighted imaging (DWI), have been employed for predicting LVSI in CC (6, 7), the accuracy of conventional MRI based on subjective visual assessment by radiologists remains low.

Radiomics, an approach that extracts quantitative features from imaging regions of interest in an automated and high-throughput manner, can quantify tumor heterogeneity, including tumor cell density, extracellular matrix deposition, angiogenesis, and necrosis degree, thereby reflecting tissue characteristics (8). In recent years, MRI-based radiomics has been widely applied to predict pathological type, grade, parametrial invasion, LVSI, and lymph node metastasis in CC (9–12). These outstanding results suggest that MRI-based radiomics may serve as an accurate and non-invasive tool for evaluating CC by analyzing primary tumors preoperatively.

Current studies on MRI-based radiomics for assessing LVSI in CC are predominantly single-center investigations with limited sample sizes, resulting in substantial heterogeneity in the reported diagnostic performance parameters. Studies conducted by Wang et al. (13) showed that the sensitivity of MRI-based radiomics in predicting LVSI in CC was as high as 94.2%, while Cui et al. (14) reported a sensitivity of only 58.1%. Furthermore, the overall diagnostic performance of MRI-based radiomics in predicting LVSI in CC has not yet been systematically evaluated. Therefore, the purpose of this meta-analysis was to determine the diagnostic performance of radiomics based on preoperative MRI in predicting LVSI in CC.

2 Methods

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (15). The evidence-based analysis was prospectively registered in PROSPERO. Two researchers (Yang CS and Wu M) independently performed each step of the analysis, engaging in discussion to reach a consensus in case of disagreements.

2.1 Search strategy

Systematic searches were conducted in Embase, PubMed, Cochrane Library, Medline, Scopus, Wanfang, and CNKI databases up to 08/04/2024. The search formula was as follows: [("Uterine Cervical Neoplasms" [Mesh]) OR (Cervical Neoplasm, Uterine) OR (Neoplasm, Uterine Cervica) OR (Uterine Cervical Neoplasm) OR (Neoplasms, Cervical) OR (Cervical Neoplasms) OR (Cervical Neoplasm) OR (Neoplasms, Cervix) OR (Cervix Neoplasm) OR (Neoplasm, Cervix) OR (Cervix Neoplasms) OR (Cancer of the Uterine Cervix) OR (Cancer of the Cervix) OR (Cervical Cancer) OR (Cancer, Cervical) OR (Cervical Cancers) OR (Uterine Cervical Cancer) OR (Cancer, Uterine Cervical) OR (Cervical Cancer, Uterine) OR (Uterine Cervical Cancers) OR (Cancer of Cervix) OR (Cervix Cancer) OR (Cancer, Cervix)] AND [(magnetic resonance imaging) OR (MRI) OR (MR)] AND [(radiomic) OR (machine learning) OR (deep learning) OR (artificial intelligence) OR (texture)]. Additionally, the reference lists of the included studies were examined to identify further eligible publications.

2.2 Inclusion and exclusion criteria

The inclusion criteria encompassed peer-reviewed publications in Chinese and English that met the following conditions: utilization of biopsy or surgical pathology results as the gold standard; employing radiomics based on MRI as the index test for assessing LVSI in CC; ensuring blinding of radiologists and pathologists; and possessing the ability to calculate true positives, false positives, true negatives, and false negatives in both Training and Validation sets. Exclusion criteria comprised animal or laboratory studies, case reports, conference reports, comments, and responses.

2.3 Literature screening and data extraction

Duplicate publications were excluded using EndNote 21 software. The titles and abstracts of the remaining articles were thoroughly scrutinized to eliminate reviews, conference abstracts, and individual case reports. A comprehensive examination of the screened articles was performed to exclude studies that did not focus on MRI-based radiomics in predicting LVSI of CC or lacked extractable data. Furthermore, when multiple articles utilized data from the same set, only the study containing the largest number of cases and the most detailed information was included in this meta-analysis. This meticulous process resulted in the final selection of included publications.

Relevant information was meticulously extracted from each selected article, including the first author, publication year, type of research, MRI machine manufacturer and magnetic field strength, MRI sequences, segmentation details, total patient population (encompassing both training and Validation sets), method of radiomic feature selection, FIGO stage, true positive, true negative, false positive, and false negative values.

If an article reported multiple models, the model with the largest sum of sensitivity and specificity in the Training set was considered the best model for that article. Subsequently, subgroups (T2WI sequence model, T1WI-CE sequence model, multiple-sequence model, and radiomics combined with clinical factor model) were defined based on the MRI sequences from which radiomic features were extracted.

2.4 Quality assessment

Two reviewers independently assessed the methodological quality and risk of bias of the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) (16) and Radiomics Quality Score (RQS) (8) guidelines, respectively.

2.5 Meta-analysis

Meta-analysis was performed using Stata 15 (Stata Corp, College Station, TX) and Review Manager 5.4. Pooled sensitivity, specificity, DOR, positive and negative likelihood ratios (PLR and NLR), and AUC, with corresponding 95% confidence intervals (CIs), were calculated. A forest plot and a summary receiver operating characteristic (SROC) plot were generated. Heterogeneity among study results was analyzed using the chi-square test, and the extent of heterogeneity was quantitatively determined. Deek's funnel plot was employed to detect the presence of publication bias. p < 0.05 was considered statistically significant.

3 Results

3.1 Literature screening

The electronic search yielded a total of 1,670 potentially eligible citations, of which 714 studies were duplicates and 1 study was not in Chinese or English language. Subsequently, 927 studies were excluded after the assessment of title and abstract. Following a careful evaluation of the full text, an additional 15 studies were excluded. Finally, 13 articles were included, comprising 4 studies in Chinese and 9 studies in English. The flowchart of the study screening process is depicted in Figure 1.

3.2 Basic features of studies

All studies were retrospective in nature. ROIs of all studies were 3D and manually segmented. The total sample size of the studies ranged from 110 to 300. Patients in two studies were from multiple centers. MRI sequences used in all studies included T2WI-Axis, T2WI-FS-Axis, T2WI-sag, T1WI-Axis, T1WI-CE-Axis, DWI-Axis, ADC-Axis, and combinations of these sequences. Eight articles (14, 17-23) reported radiomic models based on T2WI sequences (four articles with T2WI-Sag, three articles with T2WI-Axis, and one article with T2WI-FS-Axis). Seven articles (3, 13, 14, 18, 19, 21, 22) reported radiomic models based on T1WI-CE sequences (five articles with T1WI-CE-Axis, two articles with T1WI-CE-Sag). Six articles (18, 19, 21, 22, 24, 25) reported radiomic models based on multiple sequences. Seven studies (3, 14, 21, 23-26) reported radiomic models based on the combination of radiomic features and clinical factors. Deep learning was utilized to diagnose LVSI of CC in two studies. The basic features of the included studies are presented in Table 1.

3.3 Quality of literature

The total RQS was 36, and the RQS of the articles included in this meta-analysis ranged from 12 to 16, with an average of 13.54 ± 1.33 . All studies were retrospective in design, and no studies analyzed cost-effectiveness or biological correlates. The detailed RQS is shown in Table 2.

According to QUADAS-2 guidelines, two articles scored high risk of bias in the patient selection field due to the absence of

reporting on continuous enrollment and random sampling. Four articles scored unclear risk of bias in the patient selection field as inappropriate exclusions were not reported. All other indicators exhibited low risk. Overall, the methodological quality of the included studies was at a medium level. The methodological quality of the studies is illustrated in Figure 2.

3.4 Diagnostic value of the best radiomic model

The overall sensitivity and specificity of the Training set and Validation set were 83% (95% CI: 77%–87%), 72% (95% CI: 74%–88%), and 77% (95% CI: 69%–83%), 79% (95% CI: 73%–84%), respectively. AUC, DOR, PLR, and NLR of the Training set and Validation set were 0.89 (95% CI: 0.86–0.91), 22 (95% CI: 12–40), 4.6 (95% CI: 3.1, 7.0), 0.21 (95% CI: 0.16–0.29), and 0.85 (95% CI: 0.81–0.85), 13 (95% CI: 8.0–19), 3.7 (95% CI: 2.9–4.7), and 0.29 (95% CI: 0.22–0.39), respectively. The forest plots of sensitivity and specificity are presented in Figure 3, and the SROC curve is depicted in Figure 4.

3.5 Subgroup analysis

In the subgroup analysis, the area under the curve (AUC) of radiomics combined with clinical models [0.90 (95% CI: 0.87-0.93)] was higher than that of T2WI sequence models [0.78 (95% CI: 0.74-0.81)], T1WI-CE sequence models [0.85 (95% CI: 0.82-0.88)], and multiple sequence models [0.86 (95% CI: 0.82-0.89)] in the Training set. The pooled sensitivity of radiomics combined with clinical models [83% (95% CI: 73%-89%)] was superior to that of T2WI sequence models [79% (95% CI: 71%-85%)], T1WI-CE sequence models [78% (95% CI: 67%-86%)], and multiplesequence models [78% (95% CI: 67%-87%)] in the Training set. Furthermore, the pooled specificity of radiomics combined with clinical models [86% (95% CI: 73%-93%)] outperformed that of T2WI sequence models [72% (95% CI: 67%-76%)], T1WI-CE sequence models [78% (95% CI: 68%-86%)], and multiplesequence models [79% (95% CI: 70%-87%)] in the Training set. The comprehensive results of the subgroup analysis are presented in Table 3, and the corresponding subgroup analysis plots are illustrated in Figure 5.



3.6 Heterogeneity evaluation

The I^2 statistic indicated that the overall heterogeneity for sensitivity and specificity in the Training set and Validation set were 67.55%, 81.33% and 46.17%, 31.12%, respectively. The heterogeneity for sensitivity and specificity of studies (Training set) with T2WI sequence models, T1WI-CE sequence models, multiple-

sequence models, and radiomics combined with clinical models were 29% and 0%, 80.56% and 87.7%, 79.33% and 78.43%, and 79.40% and 77.17%, respectively. In the Validation set, the heterogeneity for sensitivity and specificity of studies with T2WI sequence models, T1WI-CE sequence models, multiple-sequence models, and radiomics combined with clinical models were 52.44% and 72.59%, 41% and 72.64%, 0% and 18.75%, and 0% and 70%, respectively.

Author (years)	Type of research	MRI	Sequence	Sample size	Training set	Validation set	Segmentation	ROI	Radiomics feature reduction	FIGO staging
He YM (2022) (20)	Retro	Philips, 3.0 T	T2WI-sag	110	77	33	Manually	3D	LASSO, LR	IB-IIA
Jia YJ (2023) (26)	Retro	Philips, 3.0 T	T2WI-axis, ADC-axis, T1WI-CE-axis	168	117	51	Manually	3D	mRMR LASSO	IB-IIA
Lin BJ (2024) (23)	Retro	Siemens, 3.0 T	T2WI-sag	178	142	36	Manually	3D	LASSO	NA
Wang HB (2021) (19)	Retro	Siemens, 3.0 T	T2WI-FS-axis, DWI-axis, T1WI-CE-sag	134	91	43	Manually	3D	LASSO	IA-IIA
Yu HQ (2022) (21)	Retro	GE, 3.0 T	T2WI-axis, T1WI-CE-axis	123	87	36	Manually	3D	mRMR LASSO	IA-IIIC
Cui LP (2022) (14)	Retro	Siemens, 3.0 T	T2WI-axis, T1WI-CE-axis	163	108	55	Manually	3D	LASSO, LR	IA-IIA
Hu QM. (2022) (22)	Retro	Siemens, 1.5/ 3.0 T	T2WI-axis, T1WI-axis, T1WI-CE-axis, DWI-axis	276	195	81	Manually	3D	mRMR, LASSO	IA-IB
Hua QW, 2022 (18)	Retro	Siemens, 3.0 T	T1WI-CE- axis√ T2WI-sag	167	111	56	Manually	3D	SVM	NA
Li ZC (2019) (3)	Retro	GE, 1.5 T	T1WI-CE-axis	105	70	35	Manually	3D	Univariate LR, mRMR	NA
Wang S. (2019) (17)	Retro	NA	T2WI-axis	120	80	40	Manually	3D	LASSO	IB-IIB
Wang SX (2023) (13)	Retro	Siemens 1.5/ 3.0 T	T1WI-CE-axis	300	198	102	Manually	3D	LASSO	I-III
Wu Y. (2023) (25)	Retro	Siemens, 1.5/ 3.0 T	T1WI-axis, T2WI-FS-axis, T1WI-CE-axis	168	129	39	Manually	3D	Spearman, LASSO, LR	IB-IIB
Xiao ML. (2022) (24)	Retro	Siemens 1.5 T	T1WI-axis, T2WI-FS-axis, T1WI-CE-axis, DWI-axis, ADC-axis	233	154	79	Manually	3D	LASSO	IB-IIB

TABLE 1 The basic information of literatures.

Retro, retrospective; D, dimensionality; T, Tesla; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; T2WI-FS, T2-weighted imaging fat suppression; T1WI-CE, contrast-enhanced T1 weighted imaging; SVM, support vector machine; LR, logistic regression; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient; LASSO, least absolute shrinkage and selection operator; mRMR, max-relevance and min-redundancy; NA, have no data.

TABLE 2 Radiomics quality scores of the included studies.

Study criteria	He YM (2022) (20)	Jia YJ (2023) (26)	Lin BJ (2024) (23)	Wang HB (2021) (🔊)	Yu HQ (2022) (21)	Cui LP (2022) (14)	Hu QM. (2022) (22)	Hua WQ (2022) (08)	Li ZC (2022) ()	Wang S. (2019) ()	Wang SX. (2023) (🙁)	Wu Y. (2023) (25)	Xiao ML. (2022) (24)
Image protocol quality	1	1	1	1	1	1	1	1	1	1	1	1	1
Multiple segmentations	0	1	0	1	1	1	1	1	0	0	0	1	1
Phantom study	1	1	1	1	1	1	1	1	1	1	1	1	1
Imaging at multiple time points	0	0	0	0	0	0	0	0	0	0	0	0	0
Feature reduction	3	3	3	3	3	3	3	3	3	3	3	3	3
Multivariable analysis	1	1	1	1	1	1	1	1	1	1	1	1	1
Biological correlates	0	0	0	0	0	0	0	0	0	0	0	0	0
Cutoff analysis	0	0	0	0	0	0	0	0	0	0	0	0	0
Discrimination statistics	0	0	0	0	0	0	0	0	0	0	0	0	0
Calibration statistics	0	0	0	0	0	0	0	0	0	0	0	0	0
Prospective study	0	0	0	0	0	0	0	0	0	0	0	0	0
Validation	1	1	1	1	1	1	1	1	1	1	2	2	1
Gold standard	2	2	2	2	2	2	2	2	2	2	2	2	2
Potential clinical applications	2	2	2	2	2	2	2	2	2	2	2	2	2
Cost- effectiveness analysis	0	0	0	0	0	0	0	0	0	0	0	0	0
Open Science and date	1	1	1	1	1	1	3	3	3	1	1	3	3
Total score	12	13	12	13	13	13	15	15	14	12	13	16	15

3.7 Publication bias

Deek's funnel plots were constructed for the included studies to assess potential publication bias. The results demonstrated that overall studies distinguishing LVSI positive and negative exhibited an approximately symmetrical distribution around the central axis. The *p*-values of the Training set and Validation set were 0.52 and 0.08, respectively (presented in Figure 6). In the subgroup analysis, the *p*-values of the Training set and Validation set in studies with T2WI sequence models, T1WI-CE sequence models, multiplesequence models, and radiomics combined with clinical models were 0.53 and 0.25, 0.64 and 0.53, 0.45 and 0.14, and 0.13 and 0.24, respectively. All *p*-values exceeded the 0.05 threshold, suggesting no significant evidence of publication bias.

4 Discussion

LVSI is a microscopic characteristic of tumors and is an important independent predictor of poor prognosis in CC (27). Previous studies have shown that the 5-year survival rate of CC patients with LVSI is significantly lower than that of patients without LVSI (28, 29). Routine MRI, including DWI (30), intravoxel incoherent motion MRI (31), and DCE-MRI (32), has



FIGURE 2

Results of Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). (A) Bias risk assessment results of included studies. (B) Risk of bias and applicability concerns summary.





Forest plot of sensitivity and specificity of the best radiomic model based on MRI for predicting LVSI of CC in the Training set (A) and Validation set (B), respectively.



TABLE 3 The results of subgroup analysis.

Model	No.	AUC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	PLR	NLR	DOR
Training set							
T2WI	8	0.78(0.74-0.81)	0.79(0.71-0.85)	0.72(0.67-0.76)	2.8	0.30	10
T1WI-CE	7	0.85(0.82-0.88)	0.78(0.67-0.86)	0.78(0.68-0.86)	3.6	0.28	13
Multiple sequence	6	0.86(0.82-0.89)	0.78(0.67-0.87)	0.79(0.70-0.87)	3.8	0.27	14
Radiomics+clinical	7	0.90(0.87-0.93)	0.83(0.73-0.89)	0.86(0.73-0.93)	5.9	0.20	29
Validation set							
T2WI	8	0.77(0.73-0.80)	0.74(0.63-0.83)	0.66(0.48-0.80)	2.2	0.39	6
T1WI-CE	7	0.74 (0.70-0.78	0.75(0.65-0.82)	0.59(0.44-0.71)	1.8	0.43	4
Multiple sequence	6	0.84(0.81-0.87)	0.81(0.73-0.86)	0.77(0.69-0.84)	3.6	0.25	14
Radiomics+clinical	7	0.88(0.85-0.90)	0.80(0.72-0.86)	0.82(0.76-0.87)	4.4	0.25	18

Studynt		SENSITIVITY (KIN CI)	StudyN		SPECIFICITY (MAK O)	Shudyni		SENSITIVITY (ISN CI)	Studyld		SPECIFICITY (KIN CI)
Wang 3/2019		0.78 (0.00 - 0.01)	Wang 3(2010		0.07 (0.33 - 0.70)	Wang 3/2019		0.88 (8-42 - 1.80)	Wang 302018		0.84 (0.45 - 0.80)
Hue WG/0022		0.64 (0.48 - 0.70)	Here WG(0022		a.70 pi.86 - 0.8 m	Hue WG(2022		0.64 (3.41 - 0.83)	Hue WG(0822		0.64 (2.45 - 0.80)
Hu QM/2022		0.79 (0.64 - 0.81)	Hu GM/2022		0.77 (0.05 - 0.04)	Hu QM02022		0.77 (0.48 - 0.85)	He GM/2022	_ .	0.36 (8.16 - 0.56)
Cui UP/2822		0.65 (0.48 - 0.74)	Cui LP(2822		0.00 (0.00 - 0.00)	Cui UP(2822		0.82 (9.69 - 0.95)	Cui LP/2822		0.42 (8.25 - 0.81)
Va #0/2822		0.61 (0.78 - 0.67)	Va #6/2822		4.76 (0.55 - 0.63)	Va #6/2822		0.63 (3.58 - 0.64)	Va #0/2822		0.67 (8.41 - 0.87)
Mang 149/2921		0.83 (0.75 - 0.82)	Mang HB/2821		0.02 (0.00 - 0.02)	Mang HB(2821		0.77 (2.56 - 0.91)	Marg H0(2021		0.82 (8.57 - 0.96)
Lin But282H		0.78 (0.42 - 0.87)	Lin 6//2824		6.72 (5.81 - 0.81)	Lin 84/2824		0.81 (2.64 - 0.94)	Lin 63/2824		0.60 (2.56 - 0.81)
He VM0822		0.89 (3.74 - 0.84)	He VM0000		0.07 (0.30 - 0.74)	He YM0002	_	0.38 (8.17 - 0.84)	He VM2022	-	1.00 (0.76 - 1.00)
COMBRED		0.780.71-0.85	COMBINED		0.72(0.870.78)	COMBINED		0.74(0.63 - 0.83)	COMBINED		0.65(0.48-0.60)
		Q = 10.91, df = 7.00, p = 0.02			Q = 9.28.4f = 7.00.p = 0.23			Q = 14.72, df = 7.00, p = 0.04			Q = 25.53. # = 7.08. p = 0.00
A		12 = 54.42 (24.34 - 90.64)		a. a.	12 = 24.30 (0.00 - 83.79)	D		12 = 52.44 (14.38 - 80.50)		0.2 1.6	12 = 72.58 (12.85 - 82.22)
A	0.8 SENSITIVITY 1.8			a4 specificity as		В	0.2 SENSITIVITY 1.8			0.2 SPECIFICITY 1.0	
ShubyM		SENSITIVITY (KIN CI)	Shubyld		SPECIFICITY (RNI CI)	Shutyit		SENSITIVITY (KIN C)	Studyld		SPECIFICITY (IRN C)
Wang 5102823		0.04 (2.08 - 0.04)	Wang \$152823		0.58 (2.48 - 0.69)	Wang 10/2823		0.88 (8.75 - 0.85)	Wang \$152823		0.02 (0.37 - 0.87)
Wang 2022223		0.55 (0.36 - 0.74)	U 20/2819		0.55 (0.46 - 0.56)	Wang 1002023		0.89 (0.19 - 0.81)	Wang 0002023		0.21 (0.07 - 0.42)
Hue WG/2022		0.75 (0.00 - 0.817)	Hus WG/2822		0.08 (0.03 - 0.77)	Hue WGr2922		0.73 (0.08 - 0.84)	Hue WG/2822		0.66 (0.59 - 0.75)
Ho GM/2922		0.77 (0.01 - 0.04)	Hu QM/2822		0.79 (8.04 - 0.66)	Hu QM(2222		0.85 (0.55 - 0.94)	Hu QM/2822		0.79 (0.59 - 0.82)
Cor UP/2822		0.65 (0.48 - 0.74)	Gui UM2822		0.81 (0.81 - 0.81)	Gei UP/2822		0.84 (0.41 - 0.83)	Gui LPV2822		0.58 (8.59 - 0.75)
Va HQ(0022		0.79 (0.04 - 0.90)	Via HG(2022		0.69 (8.73 - 0.95)	Va HQ(2022		0.56 (8.51 - 0.76)	Ve HG(2022		0.67 (8.41 - 0.87)
Mang H8/2821		0.01 (0.00 - 0.01)	Mang HB/2821		0.82 (2.66 - 0.82)	Mang HBr2821		0.77 (2.56 - 0.91)	Mang HB/2821		0.78 (8.58 - 0.80)
OCMEHED	\diamond	0.78(0.07 - 0.80)	0046460	\Rightarrow	0.76(0.00 - 0.00)	COMBRICO	\Leftrightarrow	0.75(0.69 - 0.82)	0048460	\Leftrightarrow	0.08(0.44 - 0.71)
		Q = 30.07. df = 0.00. p = 0.00			Q = 48.78. df = 0.00. p = 0.00			Q = 10.17, df = 0.00, p = 0.12			Q = 21.90. # = 0.00. p = 0.00
C	0.4 SENSITIVITY 1.0	12 + 80.58 (98.82 - 94.31)		84 SPECIFICITY 18	12 = 87.70 (80.00 + 86.40)	D	9.3 SENSITIVITY 18	12 = 41.00 (0.00 - 92.13)		al and for all and the second	12 - 72.04 (01.62 - 63.66)
Shutyet		SENSITIVITY (HSN CO	Studyle		SPECIFICITY (IRN CO	Skubyld	1	SENSITIVITY (RN CO	Shutyle	1	SPECIFICITY (MIN OI)
Xiao ML/2022		0.67 (0.57 - 0.75)	Xiao ML/2022		0.35 (0.14 - 0.40)	Xiao ML/2022		0.83 (0.70 - 0.80)	Xiao ML/2022		
We 1/2823											0.71 (0.52 - 0.60)
		0.89 (0.74 - 0.84)	We 1/2823		0.38 (0.26 - 0.47)	Wo 112823		0.76 (0.43 - 0.66)	We 1(2023		0.71 (0.52 - 0.60) 0.60 (0.71 - 0.60)
Hue WGr2022		0.89 (0.79 - 0.84) 0.79 (0.40 - 0.87)	Wu 1/2823		0.38 (8.28 - 0.47) 0.31 (8.21 - 0.44)	We YISES					
								0.78 (2.43 - 0.66)	We 112823		8.00 (6.71 - 0.00)
Hua WG(2022		0.79 (2.66 - 0.87)	Hua WG/2022		0.31 (8.21 - 0.44)	Hue WG/2022		0.79 (0.43 - 0.66) 0.73 (0.60 - 0.66)	We 1/2823		8.00 (0.71 - 0.00) 8.00 (0.00 - 0.00)
Hua WG(2022		0.79 (2.49 - 0.87) 0.77 (2.49 - 0.84)	Hua WG(2022 Hu GM(2022		0.31 (3.21 - 0.44) 0.18 (3.08 - 0.39)	Hun WG/2022		0.79 (0.43 + 0.00) 0.73 (0.50 + 0.60) 0.92 (0.64 + 1.00)	Wa YIOB23 Haa WGIOB22 Ha GMIOB22		6.88 (5.71 - 0.94) 6.88 (5.80 - 0.94) 6.77 (5.51 - 0.97)
Hua WG/2022 Hu GM/2022 Ya HG/2022		0.33 (246) - 0.87) 0.37 (246) - 0.84(0.69 (244) - 0.25)	Hee WG/2022 He GM/2022 Ya HG/2022		0.31 (8:21 - 0.44) 0.49 (8:00 - 0.39) 0.09 (8:00 - 0.33)	Hua WG2022		0.75 (0.45 - 0.65) 0.77 (0.60 - 0.66) 0.42 (0.64 - 1.60) 0.63 (0.56 - 0.66)	Wu V2023 Hua WG2022 Hua GM2022 Vu HG2022		8.00 (0.71 - 0.00) 8.00 (0.00 - 0.00) 8.71 (0.01 - 0.07) 9.03 (0.50 - 0.00)
Hua WG/2022 Hu GM/2022 Ya HG/2022		0.33 (246) - 0.87) 0.37 (246) - 0.84(0.69 (244) - 0.25)	Hua WG/2022 Hu GM/2022 Ya HG/2022		0.31 (8:21 - 0.44) 0.49 (8:00 - 0.39) 0.09 (8:00 - 0.33)	Hua WG2022		0.75 (0.45 - 0.65) 0.77 (0.60 - 0.66) 0.42 (0.64 - 1.60) 0.63 (0.56 - 0.66)	Wu V2023 Hua WG2022 Hua GM2022 Vu HG2022		8.00 (0.71 - 0.00) 8.00 (0.00 - 0.00) 8.71 (0.01 - 0.07) 9.03 (0.50 - 0.00)
Hear WG2022 Hear GM20222 Ya HG20222 Maang HG20221		0.39 (244) - 0.87 0.37 (244) - 0.86 0.69 (244) - 0.25 0.95 (244) - 0.96	Hear WG/2022 Hear GM/2022 Via HG/2022 Wang HG/2022		0.31 (p.21 - 0.44) 0.44 (p.06 - 0.34) 0.04 (p.06 - 0.35) 0.11 (p.06 - 0.25)	Hwa WG0822 Hu GM0822 Va H6/8522 Mang H6/2521		3.75 p.40 - 3.86 3.75 p.40 - 3.86 3.80 p.44 - 1.00 3.80 p.44 - 3.96 3.87 p.46 - 3.96	Wa VI2023 Hee WG20022 He GM20022 Va HG20022 Wang HG2022		888371-886 888378-886 871381-886 871381-886 888378-886
Hua W00222 Hu GM0822 Ya K00922 Waaq H00227		0.79 (0.44 - 0.47) 0.77 (0.44 - 0.44) 0.46 (0.44 - 0.72) 0.42 (0.42 - 0.44) 0.42 (0.42 - 0.44)	Hear WG/2022 Hear GM/2022 Via HG/2022 Wang HG/2022		0.31 (p.21 - 0.44) 0.14 (p.04 - 0.34) 0.06 (p.04 - 0.25) 0.11 (p.04 - 0.25)	Nux W00822 Nu GM0922 Nu H00822 Mung H00821 O(MdHCD)		1.77 (p. 41 - 6.40) 1.77 (p. 41 - 6.40) 1.67 (p. 41 - 1.40) 1.67 (p. 41 - 6.40) 1.77 (p. 41 - 6.40) 1.67 (p. 41 - 6.40)	Wa VI2023 Hee WG20022 He GM20022 Va HG20022 Wang HG2022		1.00 (2.17 - 0.00) 1.01 (2.01 - 0.00) 1.01 (2.01 - 0.00) 1.01 (2.01 - 0.00) 1.01 (2.01 - 0.00)
Hua W00222 Hu GM0022 V H00022 Haag H00227		0.77 (541 - 647) 0.77 (541 - 648) 0.68 (541 - 649) 0.82 (541 - 649) 0.82 (541 - 649) 0.92 (541 - 649) 0.92 (541 - 649) 0.92 (541 - 649) 0.00	Hear WG/2022 Hear GM/2022 Via HG/2022 Wang HG/2022		0.33 (5 21 - 0.44) 0.14 (5 0.4 - 0.35) 0.17 (5 0.4 - 0.35) 12 (2 0.1 - 0.35) 0 + 33 0.4 + 4 0.6 + + 0.04	Hua WO1922 Hua GM3922 Huang H01922 GCMRHCD		 1.17 (р.нт але) 1.77 (р.нт але) 1.88 (р.нт але) 1.88 (р.нт але) 1.97 (р.нт але) 	Wa VI2023 Hee WG20022 He GM20022 Va HG20022 Wang HG2022		1.889 (2.71-0.00) 1.899 (2.01-0.00) 1.879 (2.01-0.00) 1.899 (2.01-0.00) 1.899 (2.01-0.00) 1.779 (201-0.00) 0.1 (2.11-0.01) (2.10)
на 803822 на 080822 ч #03822 выезно3827 сонивно		0.77 (244 - 0.47) 0.77 (244 - 0.49) 0.87 (244 - 0.57) 0.87 (244 - 0.47) 0.87 (244 - 0.49) 0.97 (244 - 0.49) 0.97 (244 - 0.49) 0.97 (244 - 0.49)	Hua WG2022 Hu GM2022 Ya HG2022 Hung HG2027 CC468HK23	,	6.37 (9.37 - 6.44) 6.37 (9.04 - 6.30) 6.37 (9.04 - 6.30) 6.7 (9.04 - 6.30) 6.7 (9.04 - 6.30) 6.7 (9.04 - 9.04) 6.7 (9.04	ны 900000 нь 600000 чэ ноосон соокексо F			We Y0223 Hua W02023 Hua W02023 Hua W02023 Wang H02027		1.000 (27) - 0.000 1.070 (20) - 0.000 1.070 (20) - 0.000 1.070 (20) - 0.000 1.770
Hua W00222 Hu GM0822 Ya K00922 Waaq H00227		0.77 (541 - 647) 0.77 (541 - 648) 0.68 (541 - 649) 0.82 (541 - 649) 0.82 (541 - 649) 0.92 (541 - 649) 0.92 (541 - 649) 0.92 (541 - 649) 0.00	Hear WG/2022 Hear GM/2022 Via HG/2022 Wang HG/2022	,	0.33 (5 21 - 0.44) 0.14 (5 0.4 - 0.35) 0.17 (5 0.4 - 0.35) 12 (2 0.1 - 0.35) 0 + 33 0.4 + 4 0.6 + + 0.04	Nux W00822 Nu GM0922 Nu H00822 Mung H00821 O(MdHCD)		 1.17 (р.нт але) 1.77 (р.нт але) 1.88 (р.нт але) 1.88 (р.нт але) 1.97 (р.нт але) 	Wa VI2023 Hee WG20022 He GM20022 Va HG20022 Wang HG2022		1.889 (2.71 - 8.00) 1.889 (2.00 - 8.00) 1.77 (2.81 - 8.00) 1.889 (2.00 - 8.00) 1.77 (2.00 - 8.00) 0.4 - 4.11, 47 - 1.00, 57 - 8.20
на 803822 на 080822 ч #03822 выезно3827 сонивно		0.77 (244 - 0.47) 0.77 (244 - 0.49) 0.87 (244 - 0.57) 0.87 (244 - 0.47) 0.87 (244 - 0.49) 0.97 (244 - 0.49) 0.97 (244 - 0.49) 0.97 (244 - 0.49)	Hua WG2022 Hu GM2022 Ya HG2022 Hung HG2027 CC468HK23	,	41930-149 41930-149 41930-149 41930-149 41930-149 41930-149 41930-149 41930-149 41930-14940-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-14940-1494 41940-1494	5444 600000 F		4.12 x 4.344 4.12 x 4.12 x 4.144 4.12 x 4.144 4.144 4.144 4.144 4.	We Y0223 Hua W02023 Hua W02023 Hua W02023 Wang H02027		4.0271.000 4.0270.000 4.0270.000 4.0270.000 4.0270.000 4.0270.000 4.0270.000 4.0270.000 4.0270.000
на 803822 на 080822 ч #03822 выезно3827 сонивно		0.77 (244 - 0.47) 0.77 (244 - 0.49) 0.87 (244 - 0.57) 0.87 (244 - 0.47) 0.87 (244 - 0.49) 0.97 (244 - 0.49) 0.97 (244 - 0.49) 0.97 (244 - 0.49)	Hua WG2022 Hu GM2022 Ya HG2022 Hung HG2027 CC468HK23	,	6.37 (9.37 - 6.44) 6.37 (9.04 - 6.30) 6.37 (9.04 - 6.30) 6.7 (9.04 - 6.30) 6.7 (9.04 - 6.30) 6.7 (9.04 - 9.04) 6.7 (9.04	чаниян чаниян чаниян голинен F		4.17.00.186 4.17.00.100.100.100000000000000000000000	Wu YOZISI Huu WO3022 Yu WO3022 Yu WO3022 Goodeenco Shaqad	arconor à	4.0271.389 4.0271.389 4.0293.39 4.0293.39 4.0293.39 4.0294.39 4.0294.39 4.0294.39 4.0294.3004.3004.5004.5004.5004.5004.5004.500
ны 4002022 нь 0402022 ч на 0402027 сонивеко Е		11240 44 17264 44 176	Hua WG2022 Hu GM2022 Ya HG2022 Hung HG2027 CC468HK23	,	41930-149 41930-149 41930-149 41930-149 41930-149 41930-149 41930-149 41930-149 41930-14940-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41930-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-1494 41940-14940-1494 41940-1494	на изата 14-инала 14		472 94 140 472 94	ин 1089 нь ислява и сайора ини 10922 ини 10922 ини 10922 ини 10922 ини 10922 ини 10922 ини 10922 ини 10922		4 4 2 3 7 4 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2
ны 9001852 нь 9001852 ч на 901852 Соменко Соменко Виличи Хаа 9010522		4.73.61.149 4.77.61.148 4.82.81.419 4.82.81.419 4.82.81.419 4.94.91.419 4.94.91.919 4.94.919 4.94.919 4.94.919 4.94.919 4.94.919 4.94.91 4.94.94.91 4.94.94.91 4.94.91 4.94.91 4.94.91 4.94.91 4.94.91	Hua WASE22 Hu GM3022 Yu H09022 Wang H05227 COMERCD ShanyA	,	андан аң андан ан андан ан андан ан ан ан ан ан ан ан ан ан ан ан ан ан а	n. name n		472 44 - 149 472 44 - 149 472 44 - 149 477 46 - 479 477 47 47 49 477 47 47 47 47 477 477 477 477 477 477 477 4	6.1933 14.1937 15.0937 10.0937 10.0937 10.0937 10.0937 10.0937 10.0937 10.0937 10.0937 10.0937		44271 Alf 44284 Alf 44294 Alf
ны MODES нь GM3937 ч H00927 Соненко Соненко Виними Милотет чи чолования Соненко Сон	* asamon *	47247.149 472741.144 482941.109 482921.149 47497.149 47497.149 47497.149 47497.149 47497.149	Hun WARDER Hun GMIRER Hung HIRER GCGBBHCD GLUBH Hung HI Hung H	,		на волот часторото часторото насторото развити на волото на волото на на волото на на волото на на волото на на на на волото на на на на на на на на на на на на на		412 24 3 44 122 24 4 46 122 2	No.1223 No.0223 No.0223 No.0223 No.0224 No.0224 No.0225 No.02555 No.02555 No.02555 No.02555 No.02555 No.02555 No.025	arconor à	44271 Alf 44271 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44744 Alf
ны числяя чь связяя чь связяя чь соняяко соняяко В В мы числяя чь числяя чь числяя чь числяя	* asamon *	47247.102 47274.104 48294.00 48295.00 4825	Hua 940/2022 Hua 940/2022 Huang Holi 2021 Huang Holi 2021 Huan Mul 2022 Huan Mul 2022 Huan Mul 2022	,		сочаная 1.000 вида сонаная сонаная сонаная поланая сонана сонаная сонананая сонаная сонаная сонаная сонаная сонаная сонана сонана сонананая сонана сонананая сонананая сонанана сонанана сонанананая сонанананана сонанананана сонанананананананананананананананананана		472 94 149 172 94	ж. 1223 144 (122) 14 (122) 15		4.027.04 4.027.04 4.020.
ны числост чь сволост чь сволост чь сволост чь сволост нь числост нь сволост нь сволост нь сволост нь сволост нь сволост нь сволост	* asamon *	4 7 24 7 4 4 4 4 7 4 7 4 7 4 4 4 4 4 7 4 7	1000000	,		на волот часторото часторото насторото развити на волото на волото на на волото на на волото на на волото на на на на волото на на на на на на на на на на на на на		412 24 3 44 122 24 4 46 122 2	No.1223 No.0223 No.0223 No.0223 No.0224 No.0224 No.0225 No.02555 No.02555 No.02555 No.02555 No.02555 No.02555 No.025		44271 Alf 44271 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44274 Alf 44744 Alf
No. 1993 (1993) No. 1993 (1993) No. 1993 (1993) Contraction Contra		47240.455 47240.455 48244.57 4824		,		стерия политично по		4 19 24 149 19 24 149 19 24 149 19 25 149 10 25 149			4.0271.000 4.0271.000 4.0284.000 4.0284.000 4.0284.000 4.0294.0000 4.0294.0000 4.0294.0000 4.0294.0000 4.0294.0000 4
No. 1993 (1993) No. 1993 (1993) No. 1993 (1993) Contraction Contra		47240.455 47240.455 48244.57 4824		,		стерия политично по		4 19 24 149 19 24 149 19 24 149 19 25 149 10 25 149			4.0271.000 4.0271.000 4.0284.000 4.0284.000 4.0284.000 4.0294.0000 4.0294.0000 4.0294.0000 4.0294.0000 4.0294.0000 4
••••••••••••••••••••••••••••••••••••••		1972 01 1991 1972 01 1992 1982 01 1993 1992 01 1993 1993 01 1993 01 1993 01 1993 1993 01 199	1000000 and 100000 and 1000000 and 10000000 and 10000000 and 10000000 and 1000000000000000000000000000000000000					4 19 24 1 400 19 24 1 400 19 24 1 400 19 25 4 1 400 10 4 1 400 10 4 1 400 10 4 100 100 100 100 100 100 100 100 100 100	1000 00 100 1000 00 10 1000 00 1000 00000000		40271 400 40274 400 40274 400 40284 400 400 400 400 400 400 400 400 400 40
••••••••••••••••••••••••••••••••••••••			1000000 and 100000 and 1000000 and 10000000 and 10000000 and 10000000 and 1000000000000000000000000000000000000					4 12 2 - 1 - 12 4 4 2 2 - 2 - 12 4 4 2 2 - 2 - 12 4 4 2 2 - 2 - 12 4 4 - 2 - 2 - 2 - 12 4 4 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -			

FIGURE 5

Forest plot of sensitivity and specificity of different subgroups. Forest plot of sensitivity and specificity of radiomic models based on T2WI sequences in the Training set (A) and Validation set (B). Forest plot of sensitivity and specificity of radiomic models based on T1WI-CE sequences in the Training set (C) and Validation set (D). Forest plot of sensitivity and specificity of radiomic models based on multiple sequences in the Training set (E) and Validation set (F). Forest plot of sensitivity and specificity of models based on radiomics combined with clinical factors in the Training set (G) and Validation set (H).

been used to predict LVSI of CC before surgery based on the nakedeye observation and diagnostic experience of radiologists. However, the diagnostic efficacy of LVSI based on routine MRI is low and cannot meet clinical requirements. With the development of medical imaging technology, radiomics has found wide applications in predicting LVSI of cervical cancer. This study adopts a meta-analysis method to summarize the value of radiomics based on MRI in assessing LVSI of CC. The results of this



study show that the comprehensive analysis indices of MRI radiomics evaluation for estimating LVSI of cervical cancer, combining sensitivity and specificity, were 83% (95% CI: 77%–87%) and 72% (95% CI: 74%–88%), respectively. The area under the SROC curve was 0.89 (95% CI: 0.86–0.91), suggesting that radiomics based on MRI is an effective, non-invasive, and reliable method for predicting LVSI of CC. Deek's funnel plot shows no publication bias, suggesting that the results of this study are reliable. Similar meta-analyses have also demonstrated the capability of radiomics based on MRI in assessing LVSI of endometrial carcinoma (33).

In addition, in the subgroup analyses, we found that the AUC values of studies using radiomics combined with clinical factor models [0.90 (0.87–0.93)] to assess LVSI of CC were higher than those of T2WI sequence models [0.78 (0.74–0.81)], T1WI-CE sequence models [0.85 (0.82–0.88)], and multiple-sequence models [0.86 (0.82–0.89)]. Previous studies indicated that lymph node metastasis and high FIGO stage are independent risk factors for predicting LVSI in CC (34). Therefore, the diagnostic accuracy of radiomic models may increase when clinical features are added in detecting LVSI. A meta-analysis conducted by Li et al. (35) also showed that the diagnostic accuracy of radiomic models in which clinical factors were added increased significantly in detecting lymph node metastasis.

Different MRI sequences reflect different aspects of tumor information. In theory, the diagnostic performance of multisequence models, which collect multiple-diameter information from different sequences and reflect tumor information more comprehensively, should be better than that of single-sequence models (19). However, in our study, the pooled sensitivity and specificity of T2WI sequence models, T1WI-CE sequence models, and multiple-sequence models showed no significant difference. A possible reason is that the heterogeneity for sensitivity and specificity of studies was high, with a wide range (from 0% to 87.7%). This was attributed to the inconsistent stages of the patients included in the studies (some studies included patients with stage IIA and below, some included patients with stage IIB and above, and some studies did not clearly state the stage of the patients). In addition, all of the included studies were retrospectively designed. The potential risk of selective reporting of positive results is unavoidable due to the lack of predetermined study protocols. Therefore, this finding also requires well-designed and appropriate prospective randomized trials to demonstrate its validity (36, 37).

This meta-analysis has several limitations that should be acknowledged. Firstly, the original studies included in this metaanalysis have small sample sizes, which may introduce potential small sample size effects. Moreover, the high heterogeneity of individual indicators may decrease the reliability of the results to some extent. Secondly, our study only includes literature published in Chinese and English, which may introduce language bias. Third, our study did not perform subgroup analysis on studies using different equipment (Siemens, GE, and Philips) or different magnetic field strengths (3.0 T, 1.5 T).Despite these limitations, this study represents the first meta-analysis worldwide to examine the value of MRI-based radiomics in predicting LVSI of CC. The findings of this paper support the conclusions of previous studies, demonstrating that MRI-based radiomics can be effectively used to predict LVSI of CC. Furthermore, this study provides the latest and most comprehensive evidence-based medical evidence for the clinical diagnosis of CC using MRI-based radiomics.

5 Conclusion

In conclusion, this meta-analysis demonstrates the value of MRI-based radiomics in the preoperative prediction of LVSI of CC. The diagnostic performance of models combining radiomics and clinical factors was found to be superior to that of radiomics alone. However, due to the high heterogeneity among the included articles, no significant difference in diagnostic performance was observed between models based on single MRI sequences and those based on multisequence data. This finding still needs to be further verified through larger-scale, prospective studies to confirm its validity and generalizability.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

CY: Formal analysis, Methodology, Writing – original draft, Writing – review & editing. MW: Conceptualization, Formal analysis, Writing – review & editing, Writing – original draft. JZ: Investigation, Software, Writing – review & editing. HQ: Data curation, Writing – review & editing, Software. XF: Data curation, Investigation, Writing – review & editing. JY: Formal analysis, Methodology, Validation, Writing – review & editing. YL: Project administration, Supervision, Validation, Writing – review & editing, Methodology. ZQ: Project administration, Supervision, Writing – review & editing, Methodology. TS: Funding acquisition, Project administration, Supervision, Writing – review & editing, Resources.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. (2021) 71:209–49. doi: 10.3322/caac.21660

2. Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl)*. (2022) 135:584–90. doi: 10.1097/CM9.00000000002108

3. Li Z, Li H, Wang S, Dong D, Yin F, Chen A, et al. MR-based radiomics nomogram of cervical cancer in prediction of the lymph-vascular space invasion preoperatively. *J Magnetic Resonance Imaging.* (2019) 49:1420–6. doi: 10.1002/jmri.26531

4. Herr D, Konig J, Heilmann V, Koretz K, Kreienberg R, Kurzeder C. Prognostic impact of satellite-lymphovascular space involvement in early-stage cervical cancer. *Ann Surg Oncol.* (2009) 16:128–32. doi: 10.1245/s10434-008-0185-7

5. Dappa E, Elger T, Hasenburg A, Duber C, Battista MJ, Hotker AM. The value of advanced MRI techniques in the assessment of cervical cancer: a review. *Insights Imaging*. (2017) 8:471–81. doi: 10.1007/s13244-017-0567-0

6. Wang Y, Chen X, Pu H, Yuan Y, Li S, Chen G, et al. Roles of DWI and T2weighted MRI volumetry in the evaluation of lymph node metastasis and lymphovascular invasion of stage IB-IIA cervical cancer. *Clin Radiol.* (2022) 77:224– 30. doi: 10.1016/j.crad.2021.12.011

7. Song Q, Tian S, Ma C, Meng X, Chen L, Wang N, et al. Amide proton transfer weighted imaging combined with dynamic contrast-enhanced MRI in predicting lymphovascular space invasion and deep stromal invasion of IB1-IIA1 cervical cancer. *Front Oncol.* (2022) 12:916846. doi: 10.3389/fonc.2022.916846

8. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol.* (2017) 14:749–62. doi: 10.1038/nrclinonc.2017.141

9. Liu Y, Song T, Dong TF, Zhang W, Wen G. MRI-based radiomics analysis to evaluate the clinicopathological characteristics of cervical carcinoma: a multicenter study. *Acta Radiologica*. (2023) 64:395–403. doi: 10.1177/02841851211065142

10. Deng X, Liu M, Sun J, Li M, Liu D, Li L, et al. Feasibility of MRI-based radiomics features for predicting lymph node metastases and VEGF expression in cervical cancer. *Eur J Radiol.* (2021) 134:109429. doi: 10.1016/j.ejrad.2020.109429

11. Xiao ML, Fu L, Wei Y, Liu AE, Cheng JJ, Ma FH, et al. Intratumoral and peritumoral MRI radiomics nomogram for predicting parametrial invasion in patients with early-stage cervical adenocarcinoma and adenosquamous carcinoma. *Eur Radiol.* (2024) 34:852–62. doi: 10.1007/s00330-023-10042-2

12. Huang G, Cui Y, Wang P, Ren J, Wang L, Ma Y, et al. Multi-parametric magnetic resonance imaging-based radiomics analysis of cervical cancer for preoperative prediction of lymphovascular space invasion. *Front Oncol.* (2022) 11:663370. doi: 10.3389/fonc.2021.663370

13. Wang S, Liu X, Wu Y, Jiang C, Luo Y, Tang X, et al. Habitat-based radiomics enhances the ability to predict lymphovascular space invasion in cervical cancer: a multi-center study. *Front Oncol.* (2023) 13:1252074. doi: 10.3389/fonc.2023.1252074

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

14. Cui I, Yu T, Kan Y, Dong Y, Luo Y, Jiang X. Multi-parametric MRI-based peritumoral radiomics on prediction of lymph-vascular space invasion in early-stage cervical cancer. *Diagn Interventional Radiol.* (2022) 28:312–21. doi: 10.5152/dir.2022.20657

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed).* (2021) 74:790–9. doi: 10.1016/j.recesp.2021.06.016

16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med.* (2011) 155:529–36. doi: 10.7326/0003-4819-155-8-201110180-00009

17. Wang S, Chen X, Liu Z, Wu Q, Zhu Y, Wang M, et al. (2019). Radiomics analysis on T2-MR image to predict lymphovascular space invasion in cervical cancer, in: *Progress in Biomedical Optics and Imaging - Proceedings of SPIE*. Available at: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068108306&doi=10.1117%2f12. 2513129&partnerID=40&md5=85d811d5615a0dad065b945f54de7d42.

18. Hua W, Xiao T, Jiang X, Liu Z, Wang M, Zheng H, et al. Lymph-vascular space invasion prediction in cervical cancer: Exploring radiomics and deep learning multilevel features of tumor and peritumor tissue on multiparametric MRI. *Biomed Signal Process Control.* (2020) 58. doi: 10.1016/j.bspc.2020.101869

19. Wang H, Cui W, Yang W. Multi-sequence MRI-based radiomices predicting lymph-vascular space invasion in early stage cervical cancer. *Chin J Gen Pract.* (2021) 19:2088–92. doi: 10.16766/j.cnki.issn.1674-4152.002244

20. He Y, Chen S, Ma Y, Luo J, Fan L. A preliminary study on the application of nomogram based on MR histological characteristics in predicting lymphatic vascular space invasion of cervical cancer before operation. *Chin J Clin Radiol.* (2022) 41:1565–74. doi: 10.13437/j.cnki.jcr.2022.08.026

21. Yu H, Zhai J, Liu C, Xiao G, Li Q. Radiomics based on MRI for Predicting cervical cancer lymph-vascular space invasion. *Chin J Med Imaging Technol.* (2022) 38:421-6. doi: 10.13929/j.issn.1003-3289.2022.03.023

22. Hu Q, Shi J, Zhang A, Duan S, Song J, Chen T. Added value of radiomics analysis in MRI invisible early-stage cervical cancers. *Br J Radiol.* (2022) 95:20210986. doi: 10.1259/bjr.20210986

23. Lin B, Long X, Wu Z, Liang L, Lu Z, Gan W, et al. Predicting lymph-vascular space invasion in cervical cancer based on MR-T2WI with deep learning and radionic feature combined with clinical features. *Chin J Magnetic Resonance Imaging*. (2024) 15:130–6. doi: 10.12015/issn.1674-8034.2024.03.021

24. Xiao M, Li Y, Ma F, Zhang G, Qiang J. Multiparametric MRI radiomics nomogram for predicting lymph-vascular space invasion in early-stage cervical cancer. *Br J Radiol.* (2022) 95:20211076. doi: 10.1259/bjr.20211076

25. Wu Y, Wang S, Chen Y, Liao Y, Yin X, Li T, et al. A Multicenter Study on Preoperative Assessment of Lymphovascular Space Invasion in Early-Stage Cervical Cancer Based on Multimodal MR Radiomics. *J Magnetic Resonance Imaging*. (2023) 58:1638–48. doi: 10.1002/jmri.28676

26. Jia Y, Yang X, Cui Y, Quan S, Hou L. Multiparameter magnetic resonance imaging-based radiomics model for the preoperative prediction of lymph-vascular

space invasion in cervical squamous carcinoma. Chin J Anat Clinics. (2022) 27:737-44. doi: 10.3760/cma.j.cn101202-20220307-00070

27. Shigeta S, Shimada M, Tsuji K, Nagai T, Tanase Y, Matsuo K, et al. Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. *Int J Clin Oncol.* (2022) 27:1507–15. doi: 10.1007/s10147-022-02198-6

28. Biewenga P, van der Velden J, Mol BW, Stalpers LJ, Schilthuis MS, van der Steeg JW, et al. Prognostic model for survival in patients with early stage cervical cancer. *Cancer*. (2011) 117:768–76. doi: 10.1002/cncr.v117.4

29. Paik ES, Lim MC, Kim MH, Kim YH, Song ES, Seong SJ, et al. Prognostic model for survival and recurrence in patients with early-stage cervical cancer: A Korean gynecologic oncology group study (KGOG 1028). *Cancer Res Treat.* (2020) 52:320–33. doi: 10.4143/crt.2019.124

30. Mi HL, Suo ST, Cheng JJ, Yin X, Zhu L, Dong SJ, et al. The invasion status of lymphovascular space and lymph nodes in cervical cancer assessed by mono-exponential and bi-exponential DWI-related parameters. *Clin Radiol.* (2020) 75:763–71. doi: 10.1016/j.crad.2020.05.024

31. Xu C, Yu Y, Li X, Sun H. Value of integrated PET-IVIM MRI in predicting lymphovascular space invasion in cervical cancer without lymphatic metastasis. *Eur J Nucl Med Mol Imaging*. (2021) 48:2990–3000. doi: 10.1007/s00259-021-05208-3

32. Wang W, Fan X, Yang J, Wang X, Gu Y, Chen M, et al. Preliminary MRI study of extracellular volume fraction for identification of lymphovascular space invasion of cervical cancer. *J Magn Reson Imaging*. (2023) 57:587–97. doi: 10.1002/jmri.28423

33. Meng X, Yang D, Deng Y, Xu H, Jin H, Yang Z. Diagnostic accuracy of MRI for assessing lymphovascular space invasion in endometrial carcinoma: a meta-analysis. *Acta Radiol.* (2024) 65:133–44. doi: 10.1177/02841851231165671

34. Wenzel HHB, Van Kol KGG, Nijman HW, Lemmens V, van der Aa MA, Ebisch RMF, et al. Cervical cancer with </=5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI? *Gynecol Oncol.* (2020) 158:282–6. doi: 10.1016/j.ygyno.2020.04.705

35. Li L, Zhang J, Zhe X, Tang M, Zhang X, Lei X, et al. A meta-analysis of MRIbased radiomic features for predicting lymph node metastasis in patients with cervical cancer. *Eur J Radiol.* (2022) 151:110243. doi: 10.1016/j.ejrad.2022.110243

36. O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, et al. Imaging biomarker roadmap for cancer studies. *Nat Rev Clin Oncol.* (2017) 14:169–86. doi: 10.1038/nrclinonc.2016.162

37. Stanzione A, Gambardella M, Cuocolo R, Ponsiglione A, Romeo V, Imbriaco M. Prostate MRI radiomics: A systematic review and radiomic quality score assessment. *Eur J Radiol.* (2020) 129:109095. doi: 10.1016/j.ejrad.2020.109095